7,186 reports of this reaction
1.4% of all GOLIMUMAB reports
#19 most reported adverse reaction
SYNOVITIS is the #19 most commonly reported adverse reaction for GOLIMUMAB, manufactured by Janssen Biotech, Inc.. There are 7,186 FDA adverse event reports linking GOLIMUMAB to SYNOVITIS. This represents approximately 1.4% of all 511,555 adverse event reports for this drug.
Patients taking GOLIMUMAB who experience synovitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SYNOVITIS is a less commonly reported adverse event for GOLIMUMAB, but still significant enough to appear in the safety profile.
In addition to synovitis, the following adverse reactions have been reported for GOLIMUMAB:
The following drugs have also been linked to synovitis in FDA adverse event reports:
SYNOVITIS has been reported as an adverse event in 7,186 FDA reports for GOLIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
SYNOVITIS accounts for approximately 1.4% of all adverse event reports for GOLIMUMAB, making it a notable side effect.
If you experience synovitis while taking GOLIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.